Milestone Pharmaceuticals Management
Management criteria checks 2/4
Milestone Pharmaceuticals' CEO is Joe Oliveto, appointed in Mar 2017, has a tenure of 9.33 years. total yearly compensation is $2.12M, comprised of 30.6% salary and 69.4% bonuses, including company stock and options. directly owns 0.33% of the company’s shares, worth $584.58K. The average tenure of the management team and the board of directors is 5.3 years and 6.9 years respectively.
Key information
Joe Oliveto
Chief executive officer
US$2.1m
Total compensation
| CEO salary percentage | 30.63% |
| CEO tenure | 9.3yrs |
| CEO ownership | 0.3% |
| Management average tenure | 5.3yrs |
| Board average tenure | 6.9yrs |
Recent management updates
Recent updates
Milestone Pharmaceuticals: Here Comes The Revenue Ramp
Summary Milestone Pharmaceuticals Inc. remains a Strong Buy, despite recent volatility and a 37% stock decline since FDA approval of Cardamyst. Cardamyst’s rapid-acting efficacy, expanding insurance coverage, and unique market position underpin a compelling medium-term ramp in prescriptions and revenue. International expansion and a Phase 3 trial for AFib-RVR could significantly enlarge MIST’s addressable market and long-term growth prospects. With net cash, de-risked execution, and negativity priced in, positive insurance or revenue catalysts could drive a sharp MIST stock rebound. Read the full article on Seeking Alpha
FDA Approval And Shift To Self Administered Care Will Reshape This Cardiovascular Opportunity
Catalysts About Milestone Pharmaceuticals Milestone Pharmaceuticals is a cardiovascular focused company centered on CARDAMYST, an etripamil nasal spray for on demand treatment of paroxysmal supraventricular tachycardia in adults. What are the underlying business or industry changes driving this perspective?
Payer Constraints On Self Administered PSVT Care Will Challenge Near Term Progress Yet Offer Upside
Catalysts About Milestone Pharmaceuticals Milestone Pharmaceuticals is a cardiovascular-focused biopharmaceutical company with an FDA approved, self-administered intranasal therapy, CARDAMYST, for acute treatment of paroxysmal supraventricular tachycardia in adults. What are the underlying business or industry changes driving this perspective?
Acute Cardiovascular Self Administration Will Reshape Treatment Patterns And Support Long Term Thesis
Catalysts About Milestone Pharmaceuticals Milestone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for acute cardiovascular conditions, including paroxysmal supraventricular tachycardia through its intranasal etripamil product, CARDAMYST. What are the underlying business or industry changes driving this perspective?Does Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Does Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Here's Why Shareholders Should Examine Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO Compensation Package More Closely
Key Insights Milestone Pharmaceuticals' Annual General Meeting to take place on 13th of June CEO Joe Oliveto's total...Is Milestone Pharmaceuticals (NASDAQ:MIST) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...We're Hopeful That Milestone Pharmaceuticals (NASDAQ:MIST) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...We're Interested To See How Milestone Pharmaceuticals (NASDAQ:MIST) Uses Its Cash Hoard To Grow
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Companies Like Milestone Pharmaceuticals (NASDAQ:MIST) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. By way of example, Milestone...What You Need To Know About Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Investor Composition
A look at the shareholders of Milestone Pharmaceuticals Inc. ( NASDAQ:MIST ) can tell us which group is most powerful...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$68m |
| Dec 31 2025 | US$2m | US$650k | -US$63m |
| Sep 30 2025 | n/a | n/a | -US$58m |
| Jun 30 2025 | n/a | n/a | -US$56m |
| Mar 31 2025 | n/a | n/a | -US$52m |
| Dec 31 2024 | US$854k | US$602k | -US$42m |
| Sep 30 2024 | n/a | n/a | -US$43m |
| Jun 30 2024 | n/a | n/a | -US$48m |
| Mar 31 2024 | n/a | n/a | -US$55m |
| Dec 31 2023 | US$2m | US$602k | -US$60m |
| Sep 30 2023 | n/a | n/a | -US$59m |
| Jun 30 2023 | n/a | n/a | -US$59m |
| Mar 31 2023 | n/a | n/a | -US$59m |
| Dec 31 2022 | US$3m | US$584k | -US$58m |
| Sep 30 2022 | n/a | n/a | -US$62m |
| Jun 30 2022 | n/a | n/a | -US$62m |
| Mar 31 2022 | n/a | n/a | -US$44m |
| Dec 31 2021 | US$4m | US$509k | -US$43m |
| Sep 30 2021 | n/a | n/a | -US$35m |
| Jun 30 2021 | n/a | n/a | -US$32m |
| Mar 31 2021 | n/a | n/a | -US$46m |
| Dec 31 2020 | US$4m | US$470k | -US$50m |
| Sep 30 2020 | n/a | n/a | -US$60m |
| Jun 30 2020 | n/a | n/a | -US$60m |
| Mar 31 2020 | n/a | n/a | -US$61m |
| Dec 31 2019 | US$785k | US$458k | -US$55m |
Compensation vs Market: Joe's total compensation ($USD2.12M) is above average for companies of similar size in the US market ($USD1.63M).
Compensation vs Earnings: Joe's compensation has increased whilst the company is unprofitable.
CEO
Joe Oliveto (58 yo)
Mr. Joseph G. Oliveto, also known as Joe, M.B.A. has been Chief Executive Officer and President of Milestone Pharmaceuticals Inc. March 2017 and had been its Director since July 2017. He serves as Executiv...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Executive Director | 9.3yrs | US$2.12m | 0.33% $ 584.6k | |
| CFO & Executive VP of Corporate Development | 6.8yrs | US$991.91k | 0.073% $ 130.8k | |
| Chief Medical Officer | 4.4yrs | US$1.02m | 0.083% $ 148.3k | |
| Founder | no data | no data | no data | |
| Chief Operating Officer | 6.1yrs | no data | 0.037% $ 65.3k | |
| General Counsel & Chief Compliance Officer | less than a year | no data | no data | |
| Vice President of Marketing | 1.7yrs | no data | no data | |
| Vice President of Sales | 1.6yrs | no data | no data | |
| Chief Medical Advisor & Member of the Scientific Advisory Board | 6.5yrs | no data | no data | |
| SVP of Regulatory Affairs and Quality Management | no data | no data | no data | |
| Chief Commercial Officer | 8.8yrs | US$645.72k | 0.15% $ 269.1k | |
| VP & Head of Medical Affairs | 3.9yrs | no data | no data |
Experienced Management: MIST's management team is seasoned and experienced (5.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Executive Director | 9yrs | US$2.12m | 0.33% $ 584.6k | |
| Founder | 6.5yrs | no data | no data | |
| Chief Medical Advisor & Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Observer | 8.9yrs | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 3.3yrs | US$125.25k | 0% $ 0 | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 7.3yrs | US$131.75k | 0.011% $ 19.7k | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Chairman of the Board | 5.8yrs | US$154.25k | 0.048% $ 85.2k |
Experienced Board: MIST's board of directors are considered experienced (6.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/10 18:51 |
| End of Day Share Price | 2026/07/10 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Milestone Pharmaceuticals Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Patrick Trucchio | H.C. Wainwright & Co. |
| Brandon Folkes | H.C. Wainwright & Co. |
| Christopher Howerton | Jefferies LLC |